Summary
Merck & Co., Inc. reported mixed financial results for the quarter ended June 30, 2025. Total sales decreased by 2% to $15.8 billion compared to the prior year, primarily driven by lower vaccine and virology sales, partially offset by growth in oncology and cardiovascular segments. Net income attributable to Merck & Co., Inc. also saw a decline, falling to $4.4 billion from $5.5 billion in the same period last year, resulting in diluted earnings per share of $1.76, down from $2.14. Despite the top-line decline, the company announced a significant strategic move with an agreement to acquire Verona Pharma plc for approximately $10 billion to bolster its respiratory portfolio. Research and development expenses increased by 16% to $4.0 billion, driven by an upfront payment for a new license agreement and increased clinical development spending. Restructuring costs were also substantial, reflecting a new $3 billion restructuring program aimed at driving future growth and efficiency.
Financial Highlights
55 data pointsBeta
Financial Statements
Beta
| Revenue | $15.81B |
| Cost of Revenue | $3.56B |
| Gross Profit | $12.25B |
| R&D Expenses | $4.05B |
| SG&A Expenses | $2.65B |
| Net Income | $4.43B |
| EPS (Basic) | $1.76 |
| EPS (Diluted) | $1.76 |
| Shares Outstanding (Basic) | 2.51B |
| Shares Outstanding (Diluted) | 2.51B |
Key Highlights
- 1Total sales decreased by 2% to $15.8 billion in Q2 2025 compared to Q2 2024, with international sales experiencing a 15% decline.
- 2Net income attributable to Merck & Co., Inc. decreased to $4.4 billion ($1.76 EPS) from $5.5 billion ($2.14 EPS) in the prior year's quarter.
- 3Agreement to acquire Verona Pharma plc for approximately $10 billion to strengthen the respiratory disease franchise.
- 4Research and development expenses increased by 16% to $4.0 billion, largely due to a $200 million upfront payment for a license agreement with Hengrui Pharma.
- 5Significant restructuring charges of $560 million were incurred in Q2 2025 related to the newly approved 2025 Restructuring Program, with an estimated total cost of $3.0 billion.
- 6Keytruda sales grew 9% globally to $7.96 billion, demonstrating continued strength in the oncology segment.
- 7Gardasil/Gardasil 9 sales experienced a significant 55% decline due to lower demand in China and Japan, impacting the vaccine segment.
Frequently Asked Questions
Merck's sales for the quarter ended June 30, 2025, declined by 2% year-over-year. While the oncology segment, particularly Keytruda, showed strong growth, this was offset by significant declines in vaccines (primarily Gardasil/Gardasil 9 due to issues in China and Japan) and virology (Lagevrio). The company is strategically investing in growth areas like oncology and cardiovascular, and the proposed acquisition of Verona Pharma aims to bolster its respiratory pipeline. However, ongoing pricing pressures, potential government price negotiations under the IRA, and generic competition for established products like Januvia and Bridion will continue to pose headwinds. Investors should monitor the successful integration of Verona Pharma and the performance of new product launches.
Merck has initiated a new 2025 Restructuring Program with an estimated cost of $3.0 billion, aiming for annual cost savings of approximately $1.7 billion by the end of 2027, which will be reinvested into strategic growth areas. Additionally, the 2024 Restructuring Program is ongoing. In the current quarter, restructuring costs were $560 million. While these programs involve significant upfront costs and temporary disruptions, they are intended to streamline operations, optimize the real estate footprint, and improve manufacturing efficiency, which should positively impact long-term profitability and enhance the company's ability to invest in its pipeline.
Merck has entered into a definitive agreement to acquire Verona Pharma plc for approximately $10 billion. This strategic acquisition is expected to significantly enhance Merck's respiratory disease franchise with Ohtuvayre (ensifentrine), a treatment for COPD. The transaction is expected to close in the fourth quarter of 2025 and Merck anticipates capitalizing most of the purchase price as an intangible asset. While this is a substantial investment, it underscores Merck's commitment to strategic growth and pipeline expansion in key therapeutic areas.
Merck faces ongoing legal proceedings, including product liability lawsuits related to Gardasil/Gardasil 9 and Dr. Scholl's Foot Powder, as well as intellectual property and commercial litigation. The company is also subject to regulatory scrutiny, including IRS examinations concerning tax returns from 2017-2018, with proposed adjustments of approximately $1.3 billion plus penalties. Additionally, pricing pressures from healthcare reform, government drug price negotiations under the Inflation Reduction Act, and potential tariffs are significant factors that could impact future financial performance. Investors should closely follow developments in these legal and regulatory matters as they could have material financial implications.